Shield Therapeutics PLC

Shield Therapeutics PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)41.31
  • Today's Change0.31 / 0.76%
  • Shares traded28.61k
  • 1 Year change-26.07%
  • Beta1.9699
Data delayed at least 20 minutes, as of Jan 18 2022 09:04 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Shield Therapeutics plc is a United Kingdom-based commercial stage specialty pharmaceutical company. The Company specializes in the development and commercialization of late-stage pharmaceuticals which address areas of unmet medical need. The Company's lead product, Feraccru/Accrufer (ferric maltol), is a stable, non-salt-based oral therapy for adults with iron deficiency with or without anemia. Ferric maltol is approved in the United States, European Union, United Kingdom and Switzerland for the treatment of iron deficiency with or without anemia in adults. Its pipeline product candidate, PT20, is an iron-based phosphate binder that has the potential to treat patients with hyperphosphatemia related to dialysis or non-dialysis dependent chronic kidney disease (CKD). PT20 has completed its Phase II pivotal study. Its subsidiaries include Shield Therapeutics (DE) GmbH, Shield TX (UK) Limited, Phosphate Therapeutics Limited, and others.

  • Revenue in GBP (TTM)1.95m
  • Net income in GBP-13.04m
  • Incorporated2015
  • Employees16.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Spectral MD Holdings Ltd12.65m-944.16k49.78m----4.17--3.94-0.0072-0.00720.09490.0878----------------43.26---7.46-----71.920.00--195.82--139.74------
Kanabo Group PLC15.00k-2.41m53.65m----8.04--3,576.34-0.0096-0.00960.00010.0180.0039--0.0932---62.27---66.38---26.67---16,046.67--24.36--0.00------63.91------
Skinbiotherapeutics PLC0.00-1.43m56.05m7.00--10.33-----0.0097-0.00970.000.03460.00----0.00-32.98-31.20-35.80-32.97-----------1,609.800.0251------4.47---3.79--
Venture Life Group PLC27.05m347.00k57.25m119.00108.590.811321.382.120.00420.00420.23640.56090.34671.922.69227,268.900.44480.84940.53711.0140.2140.351.281.781.23--0.1643--48.8527.07161.95--28.44--
Destiny Pharma PLC0.00-5.47m63.76m14.00--6.27-----0.1058-0.10580.000.16980.00----0.00-65.43-40.73-70.34-43.29------------0.00-------14.93--284.88--
OKYO Pharma Ltd0.00-3.00m64.55m6.00--11.61-----0.0044-0.00440.000.00570.00----0.00-106.65---157.37-------------3,496.670.0182-------146.83------
Verici Dx Plc-100.00bn-100.00bn71.02m8.00------------------------------------------------------------
4d Pharma PLC490.00k-67.69m74.28m115.00--1.87--151.60-0.4438-0.44380.00340.220.0112--0.1954,260.87-154.55-32.46-182.79-35.41-----13,813.67-13,963.364.18-54.630.0248--153.08---7.88---27.01--
Yourgene Health PLC27.56m-9.86m85.04m180.00--2.47--3.09-0.0137-0.01370.03820.04750.49723.263.81153,094.60-17.79-24.79-21.58-33.6960.2957.85-35.79-53.901.34-11.620.1345--10.0849.46-400.58--27.36--
Shield Therapeutics PLC1.95m-13.04m88.49m16.00--1.73--45.40-0.0817-0.08170.01220.23630.0430.53481.54121,812.50-28.76-24.56-30.15-27.0361.3189.95-668.91-199.8717.86-451.480.00--1,344.65--70.11---29.49--
Science in Sport PLC56.04m-837.00k93.90m197.00--1.9538.641.68-0.0061-0.00610.42050.3560.86583.435.11284,446.70-1.29-9.92-1.63-11.7450.9850.27-1.49-12.971.24-6.480.0147---0.43939.7569.24--32.13--
Futura Medical plc.0.00-2.93m95.19m13.00--7.33-----0.0117-0.01170.000.04520.00----0.00-34.96-58.52-38.86-74.23-------4,391.3918.60--0.00---100.00--73.00---12.11--
C4X Discovery Holdings PLC5.64m-3.84m97.86m46.00--5.05--17.34-0.0228-0.02280.02880.08470.3635--11.15122,652.20-24.77-60.05-27.63-68.5398.4099.28-68.13-237.08---420.930.0205----82.4650.65---13.79--
Diurnal Group PLC4.37m-10.05m107.41m36.00--2.84--24.57-0.0733-0.07330.03190.22370.13930.543611.59121,416.70-32.02-43.08-35.86-50.3382.18---229.90-427.579.59--0.00---30.76---146.78------
Eco Animal Health Group Plc101.55m5.57m125.29m207.0022.471.508.841.230.08230.08231.501.230.91312.173.60490,584.5011.3110.5515.4013.1449.9348.5312.3814.622.57--0.014547.1946.4617.51109.456.21-30.72-29.40
Data as of Jan 18 2022. Currency figures normalised to Shield Therapeutics PLC's reporting currency: UK Pound GBX

Institutional shareholders

24.14%Per cent of shares held by top holders
HolderShares% Held
Hargreaves Lansdown Stockbrokers Ltd.as of 02 Nov 202111.51m5.33%
JPMorgan Asset Management (UK) Ltd.as of 10 Apr 20186.24m2.89%
Hargreaves Lansdown Asset Management Ltd.as of 02 Nov 20216.09m2.82%
Rahn+Bodmer Co.as of 02 Nov 20215.65m2.62%
USS Investment Management Ltd.as of 19 Mar 20215.07m2.35%
BlackRock Investment Management (UK) Ltd.as of 02 Nov 20215.01m2.32%
Jarvis Investment Management Ltd.as of 02 Nov 20214.95m2.29%
HSBC Bank Plc (Market-Maker)as of 02 Nov 20212.68m1.24%
IG Markets Ltd.as of 02 Nov 20212.62m1.21%
Investec Wealth & Investment Ltd.as of 02 Nov 20212.29m1.06%
More ▼
Data from 30 Sep 2021 - 03 Jan 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.